162 related articles for article (PubMed ID: 38444223)
41. FOXO1 associated with sensitivity to chemotherapy drugs and glial-mesenchymal transition in glioma.
Chen C; Han G; Li Y; Yue Z; Wang L; Liu J
J Cell Biochem; 2019 Jan; 120(1):882-893. PubMed ID: 30216501
[TBL] [Abstract][Full Text] [Related]
42. UBE2T Promotes Temozolomide Resistance of Glioblastoma Through Regulating the Wnt/β-Catenin Signaling Pathway.
Wang Y; Gao G; Wei X; Zhang Y; Yu J
Drug Des Devel Ther; 2023; 17():1357-1369. PubMed ID: 37181827
[TBL] [Abstract][Full Text] [Related]
43. BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction.
Yao Z; Yang S; Zhao H; Yang H; Jiang X
Cancer Gene Ther; 2020 Apr; 27(3-4):226-234. PubMed ID: 30518782
[TBL] [Abstract][Full Text] [Related]
44. RPL22L1, a novel candidate oncogene promotes temozolomide resistance by activating STAT3 in glioblastoma.
Chen Y; Mu Y; Guan Q; Li C; Zhang Y; Xu Y; Zhou C; Guo Y; Ma Y; Zhao M; Ji G; Liu P; Sun D; Sun H; Wu N; Jin Y
Cell Death Dis; 2023 Nov; 14(11):757. PubMed ID: 37985768
[TBL] [Abstract][Full Text] [Related]
45. NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation.
Su IC; Su YK; Setiawan SA; Yadav VK; Fong IH; Yeh CT; Lin CM; Liu HW
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175412
[TBL] [Abstract][Full Text] [Related]
46. Piperlongumine-inhibited TRIM14 signaling sensitizes glioblastoma cells to temozolomide treatment.
Kuo YY; Ho KH; Shih CM; Chen PH; Liu AJ; Chen KC
Life Sci; 2022 Nov; 309():121023. PubMed ID: 36202175
[TBL] [Abstract][Full Text] [Related]
47. Knockdown of BCL6 Inhibited Malignant Phenotype and Enhanced Sensitivity of Glioblastoma Cells to TMZ through AKT Pathway.
Song W; Wang Z; Kan P; Ma Z; Wang Y; Wu Q; Yao X; Zhang B
Biomed Res Int; 2018; 2018():6953506. PubMed ID: 30420967
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
Liang H; Chen Z; Sun L
Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
[TBL] [Abstract][Full Text] [Related]
49. Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance.
Yamamuro S; Takahashi M; Satomi K; Sasaki N; Kobayashi T; Uchida E; Kawauchi D; Nakano T; Fujii T; Narita Y; Kondo A; Wada K; Yoshino A; Ichimura K; Tomiyama A
Cancer Sci; 2021 Nov; 112(11):4736-4747. PubMed ID: 34536314
[TBL] [Abstract][Full Text] [Related]
50. Downregulation of SNRPG induces cell cycle arrest and sensitizes human glioblastoma cells to temozolomide by targeting Myc through a p53-dependent signaling pathway.
Lan Y; Lou J; Hu J; Yu Z; Lyu W; Zhang B
Cancer Biol Med; 2020 Feb; 17(1):112-131. PubMed ID: 32296580
[No Abstract] [Full Text] [Related]
51. Activated TRPA1 plays a therapeutic role in TMZ resistance in glioblastoma by altering mitochondrial dynamics.
Chen H; Li C; Hu H; Zhang B
BMC Mol Cell Biol; 2022 Aug; 23(1):38. PubMed ID: 35982414
[TBL] [Abstract][Full Text] [Related]
52. Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity.
Doan P; Nguyen P; Murugesan A; Candeias NR; Yli-Harja O; Kandhavelu M
Cells; 2021 Aug; 10(8):. PubMed ID: 34440745
[TBL] [Abstract][Full Text] [Related]
53. miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
Wei J; Qi X; Zhan Q; Zhou D; Yan Q; Wang Y; Mo L; Wan Y; Xie D; Xie J; Yang S
Biomed Pharmacother; 2015 Apr; 71():112-8. PubMed ID: 25960225
[TBL] [Abstract][Full Text] [Related]
54. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of microRNA-299-5p sensitizes glioblastoma cells to temozolomide via the MAPK/ERK signaling pathway.
Peng Y; He X; Chen H; Duan H; Shao B; Yang F; Li H; Yang P; Zeng Y; Zheng J; Li Y; Hu J; Lin L; Teng L
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30061180
[TBL] [Abstract][Full Text] [Related]
56. Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide.
Alafate W; Wang M; Zuo J; Wu W; Sun L; Liu C; Xie W; Wang J
Pathol Res Pract; 2019 Nov; 215(11):152617. PubMed ID: 31563286
[TBL] [Abstract][Full Text] [Related]
57. Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.
Lan F; Pan Q; Yu H; Yue X
J Neurochem; 2015 Sep; 134(5):811-8. PubMed ID: 25991372
[TBL] [Abstract][Full Text] [Related]
58. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X
Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123
[TBL] [Abstract][Full Text] [Related]
59. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma.
Yin J; Zeng A; Zhang Z; Shi Z; Yan W; You Y
EBioMedicine; 2019 Apr; 42():238-251. PubMed ID: 30917935
[TBL] [Abstract][Full Text] [Related]
60. Quercetin induces MGMT
Wang W; Yuan X; Mu J; Zou Y; Xu L; Chen J; Zhu X; Li B; Zeng Z; Wu X; Yin Z; Wang Q
Phytomedicine; 2023 Sep; 118():154933. PubMed ID: 37451151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
